130 related articles for article (PubMed ID: 26600960)
21. Denosumab and giant cell tumour of bone-a review and future management considerations.
Xu SF; Adams B; Yu XC; Xu M
Curr Oncol; 2013 Oct; 20(5):e442-7. PubMed ID: 24155640
[TBL] [Abstract][Full Text] [Related]
22. Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget's disease: A case report.
Tanaka T; Slavin J; McLachlan SA; Choong P
Oncol Lett; 2017 Apr; 13(4):2105-2108. PubMed ID: 28454368
[TBL] [Abstract][Full Text] [Related]
23. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
24. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
25. Role of Denosumab in Endoscopic Endonasal Treatment for Juvenile Clival Giant Cell Tumor: A Case Report and Review of the Literature.
Inoue A; Ohnishi T; Kohno S; Nishikawa M; Nishida N; Ohue S
World Neurosurg; 2016 Jul; 91():674.e1-6. PubMed ID: 27113403
[TBL] [Abstract][Full Text] [Related]
26. Giant cell tumors of the spine: has denosumab changed the treatment paradigm?
Goldschlager T; Dea N; Boyd M; Reynolds J; Patel S; Rhines LD; Mendel E; Pacheco M; Ramos E; Mattei TA; Fisher CG
J Neurosurg Spine; 2015 May; 22(5):526-33. PubMed ID: 25700239
[TBL] [Abstract][Full Text] [Related]
27. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone.
Borkowska A; Goryń T; Pieńkowski A; Wągrodzki M; Jagiełło-Wieczorek E; Rogala P; Szacht M; Rutkowski P
Oncol Lett; 2016 Dec; 12(6):4312-4318. PubMed ID: 28101196
[TBL] [Abstract][Full Text] [Related]
28. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
29. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
30. Effect of denosumab on recurrent giant cell reparative granuloma of the lumbar spine.
Akeda K; Kasai Y; Sakakibara T; Matsumine A; Takegami N; Yamada J; Sudo A
Spine (Phila Pa 1976); 2015 May; 40(10):E601-8. PubMed ID: 25955096
[TBL] [Abstract][Full Text] [Related]
31. Malignant Sarcomatous Transformation of Benign Giant Cell Tumor of Bone after Treatment with Denosumab Therapy: A Literature Review of Reported Cases.
Alaqaili SI; Abduljabbar AM; Altaho AJ; Khan AA; Alherabi JA
Cureus; 2018 Dec; 10(12):e3792. PubMed ID: 30868006
[TBL] [Abstract][Full Text] [Related]
32. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
33. Giant-cell tumor of bone: treatment options and role of denosumab.
Singh AS; Chawla NS; Chawla SP
Biologics; 2015; 9():69-74. PubMed ID: 26203221
[TBL] [Abstract][Full Text] [Related]
34. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy.
Matcuk GR; Patel DB; Schein AJ; White EA; Menendez LR
Skeletal Radiol; 2015 Jul; 44(7):1027-31. PubMed ID: 25712768
[TBL] [Abstract][Full Text] [Related]
35. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
36. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
37. Giant cell tumour of bone.
Thomas DM; Skubitz KM
Curr Opin Oncol; 2009 Jul; 21(4):338-44. PubMed ID: 19444102
[TBL] [Abstract][Full Text] [Related]
38. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
39. Denosumab Therapy in the Management of Aneurysmal Bone Cysts: A Comprehensive Literature Review.
Alhumaid I; Abu-Zaid A
Cureus; 2019 Jan; 11(1):e3989. PubMed ID: 30972268
[TBL] [Abstract][Full Text] [Related]
40. Denosumab Therapy for Giant-cell Tumor of the Lumbar Spine: A Case Report and Immunohistochemical Examination.
Yayama T; Mori K; Nakamura A; Mimura T; Imai S
J Orthop Case Rep; 2020; 10(2):76-79. PubMed ID: 32953662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
